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Abstract
Purpose: Angiogenesis is essential for tumor growth and metastases, thus bestowing obvious importance upon methodologies
which could enable its inhibition.
Materials: C57BL/6 female mice bearing a subcutaneous (s.c.) MCA205 fibrosarcoma were used.
Methods: Ten mice were divided equally into two groups. One group was injected intraperitoneally (i.p.) with 10mg tumor
necrosis factor-a (TNF-a and the other (controls) with Hanks balanced salt solution (HBSS). Tumor growth was monitored
at least twice weekly. The number of endothelial cells in the blood microvessels was assessed by immunohistostaining on
paraffin-embedded tumor tissue sections using vascular endothelial growth factor (VEGF) and Factor 8 antibodies.
Expression of the p53 gene was similarly assessed by immunohistostaining.
Results: Injection of 10mg TNF-a into the tumor-bearing mice reduced the number of endothelial cells in the blood
microvessels by 46% on day 3 post-injection which was accompanied by an increase (by 37%) in the expression of p53 in
these cells. It also inhibited tumor growth compared to the HBSS-injected group starting at 17 days post-cytokine injection.
Discussion: The antitumor in vivo effect exerted by TNF-a on established murine sarcoma s.c. tumors may be due to an
earlier effect of the cytokine on the tumor’s blood microvessels, probably through an apoptotic mechanism involving the
p53 gene.
Introduction
Angiogenesis plays an important role in the growth,
progression and metastases of different solid tumors,
including melanoma and carcinoma of breast, lung,
colon and prostate.
1,2Moreover, the numberofblood
microvessels in tumor tissues has been shown to be of
prognostic value for certain tumors.
2 Thus, the
inhibition of angiogenesis is considered to be highly
effective for assessing the growth of solid tumors.
Tumor angiogenesis is controlled by a number of
positive and negative regulators that are elaborated by
tumor cells and tumor-associated host cells, particu-
larly by tumor-associated macrophages. Such reg-
ulators include basic fibroblast growth factor (bFGF),
vascular endothelial growth factor (VEGF), trans-
forming growth factor (TGF)-, platelet-derived
growth factor (PDGF), interleukin (IL)-8 and
thrombospondin-1.
3,4
Another molecule which regulates angiogenesis is
tumor necrosis factor (TNF)-a. This molecule was
originally described as a protein that mediates a
primary hemorrhagic necrosis and the subsequent
regressionofestablishedsubcutaneous(s.c.)tumors.
5
Such antitumor effects, which usually occur within a
short period following injection of TNF-a, imply that
TNF-a may be involved in angiogenesis by destroy-
ing the tumor’s blood microvessels, thus leading to
hypoxia followed by activation of the p53 gene and
ultimately to apoptosis.
6 The evidence in support of
such a possibility, however, is controversial. In some
reported studies, the secretion of TNF-a by activated
monocytes induced angiogenesis via the production
of IL-8, VEGF and bFGF4, while other studies
showed either no effect of TNF-a on microvessel
density
7 or an anti-angiogenic effect when TNF-a
was combined with linomide
8 and lovastatin.
9
Similar to what was shown to occur in carcinoma
and melanoma, modulation of angiogenesis in
mesenchymal tumors, such as fibrosarcoma 105
and HT1080, has been demonstrated using the
AGM-1470 and thrombospondin-1 modulators,
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3,10 The effect of TNF-a on mesenchy-
mal tumors, however, remains unknown.
In the present study, we used an immunohisto-
chemistry method to analyze the effect in vivo of
TNF-a on the number of endothelial cells in the
blood microvessels of tumors in a murine fibrosar-
coma model. Our results demonstrate that an
injection of TNF-a at the same dose which had
reduced the growth rate of established s.c. MCA205
tumors in mice
11 substantially diminished the
number of endothelial cells in the blood microvessels
in that tumor.
Materials and methods
Animals
Female C57BL/6 mice were obtained from the
Animal Facility Building at the Tel-Aviv University
and were used when they were 12–20 weeks old.
Tumor
A MCA205 fibrosarcoma line, syngeneic to C57BL/6
(H2
b) mice, was kindly provided by the Surgery
Branch, National Cancer Institute, Bethesda, MD,
USA. These cells were grown in culture and under-
went passages twice weekly. Before use, the MCA205
cells were harvested by exposure for 2–3 min to
trypsin–EDTA followed by cell washing in complete
medium (CM). The CM consisted of RPMI 1640
with 10% heat-inactivated fetal calf serum (FCS),
0.1mM nonessential amino acids, 1mM sodium
pyruvate, 100mg streptomycin, 100U/ml penicillin,
0.03% fresh glutamine, 50mg/ml gentamicin and
0.5mg/ml Fungizone. All the products were pur-
chased from Biological Industries, Israel.
Cytokine
Recombinant TNF-a was purchased from
PeproTech, NJ, USA (catalog #300-01A). This
material has a specific activity of >2 10
7 units/mg
protein determined by the cytolysis of murine L929
cells in the presence of actinomycin D, and
endotoxin levels below 0.1ng/mg of rTNF-a.
In vivo model
MCA205 tumor cells were injected s.c. into the
animal’s abdomen with 5 10
5 cells/0.1ml Hanks
balanced salt solution (HBSS). When the tumors
were palpable, the mice were divided into two
groups: those in the first group were injected
intraperitoneally (i.p.) with TNF-a at 10mg/0.5ml
HBSS and those in the second group were injected
i.p. with HBSS alone. Tumor growth was deter-
mined in a blinded fashion throughout the entire
study period by the same investigator who recorded
the largest perpendicular diameters (the multiplica-
tion of which is referred to as ‘tumor area’).
11 Tumor
growth was monitored at least twice weekly.
Immunohistostaining
12
Tumor tissues were fixed in formalin and subjected
to increasing concentrations of ethanol and xylene.
The tissue was embedded in paraffin, cut into
sections 3–5mm thick and incubated with the
following antibodies: VEGF (Santa Cruz, CA,
USA, catalog #SC7269, dilution 1:200), F8
(Zymed, CA, USA catalog #18-0018, dilution
1:50) and p53 (Zymed, catalog #18-0129, dilution
1:40). The tissue sections were then incubated with
biotin-labeled goat anti-mouse antibody (Ventana,
AZ, USA) followed by exposure to avidin–perox-
idase complex (Ventana). Finally, diaminobenzidine
(DAB, Ventana) was added to serve as a substrate.
Screening of stainedtissues for positive cells
12
Each stained tissue was screened in a blinded
fashion under a microscope at  400 magnification
(0.4mm
2/field). For each tissue section, 25 different
fields were randomly selected and the number of
blood microvessels, assessed by identifying stained
endothelial cells, was scored by the same investigator
throughout the entire study. To avoid false-positive
staining, fields were selected at a relative distance
from tissue section margins.
Results
Effect of TNF on MCA205 tumor growth
Ten mice were injected s.c. with 5 10
5 MCA205
tumor cells. When tumors were palpable (usually on
days 7–10 after injection of the cells), the mice were
equally divided into two groups. The mice in one
group were injected i.p. with 10mg/0.5ml TNF, a
dose which had been found in a previous study to
exert an antitumor activity on established s.c. tumors
in mice.
13 The mice in the second group which
served as controls were injected with 0.5ml HBSS.
As shown in Fig. 1, no difference was noted in tumor
growth rate between the TNF and HBSS groups up
to day 19 after TNF injection. Thereafter, the growth
rate of tumor in the HBSS control group was
substantially higher than that in the TNF group.
Based on these findings, an i.p. injection of TNF at
10mg/mouse was selected for use throughout the
entire study.
Modulation of the number of blood microvessel endothelial
cells in the MCA205 tumors by TNF-
An immunohistochemistry method using VEGF and
F8 antibodies which react with endothelial cells was
58 A. Eisenthal et al.employed to evaluate the effect of TNF-a on the
number of blood microvessels in the MCA205
tumors. The mice bearing palpable tumors (usually
7–10 days post tumor cells injection) were injected
i.p. with 10mg/ml TNF. The control mice were
injected in the same manner with HBSS. The
animals were sacrificed at 1, 3 and 7 days after
TNF-a injection, and the tumor was removed and
fixed in formalin. After they were embedded, the
tumor tissues were cut and immunohistostained with
VEGF and F8 antibody which specifically reacts with
the endothelial cells in the blood microvessels. The
mean number (three mice in each group) standard
error of the mean (SEM) of blood microvessels,
assessed by F8-positive endothelial cells in the
HBSS-injected mice was 29.3 7.2, 63.3 15.6
and 73.3 10.0 at 1, 3 and 7 days post-injection,
respectively (Fig. 2). In the TNF-a-injected mice,
the mean number of blood microvessels assessed by
F8-positive endothelial cells was 31.7 10.0,
34.3 2.5 (P<0.05 compared to HBSS group) and
51.0 8.6 (P<0.05 compared to HBSS group) at 1,
3 and 7 days post-injection, respectively. Similarly,
when VEGF was used for identifying endothelial
cells, the mean number of blood microvessels in
the HBSS-injected mice increased from 28.0 6.1
at day 1 to 50.7 10.2 and 57.3 0.6 at 3 and 7 days
post-injection, respectively (Fig. 3), while in the
TNF-a-injected mice, the number of blood micro-
vessels increased from 27.3 10.2 at day 1 to
27.3 8.4 (P<0.05 compared to HBSS group)
and 44.7 0.6 at 3 and 7 days post-injection,
respectively.
Effect of TNF- on the expression of p53 in MCA205
tumors
It has been shown that inhibition of angiogenesis
causes apoptosis of endothelial cells via the activation
of the p53 suppressor gene.
6 Since TNF-a was found
in previous experiments to reduce the number of
endothelial cells in the blood microvessels in
MCA205 tumors, the possible involvement of p53
in this phenomenon was also addressed. For that
purpose, mice were injected with either TNF-a or
HBSS, sacrificed at various time intervals, the tumor
was removed, embedded in paraffin and then
immunohistostained with p53 antibodies. The inten-
sity of staining in endothelial cells of blood micro-
vessels was determined as following: þ1¼low
intensity, þ2¼medium intensity and þ3¼high
intensity. As shown in Fig. 4, TNF-a induced a
greater increase than HBSS in the expression of p53
Fig. 1. Effect of TNF- on the growth of MCA205 tumor.
Ten C57BL/6 mice were injecteds.c. with 5  10
5 MCA205
tumor cells. When the tumors were palpable, the mice were
injectedi.p with either 0.5ml HBSS or 10 g TNF-/0.5 ml
HBSS. Each dot represents the mean of five mice at each time
point.
Fig. 2. Effect of TNF- on the number of bloodmicrovessels
assessedby Factor 8 antibod y staining. C57BL/6 mice were
injecteds.c. with 5  10
5 MCA205 tumor cells followedby an
i.p. single injection of either 10g TNF- or HBSS. On days
1, 3 or 7, the mice were sacrificed, the tumors removed, and the
paraffin-embedded tissue sections were stained with F8 anti-
body. Each dot represents the mean number (including the
standard error of the mean [SEM]) of the blood microvessels
calculatedfrom tumors resectedfrom three d ifferent mice
*P<0.05.
Fig. 3. Effect of TNF- on the number of bloodmicrovessels
assessedby VEGF antibod y staining. C57BL/6 mice were
injecteds.c. with 5  10
5 MCA205 tumor cells followedby an
i.p. single injection of either 10g TNF- or HBSS. On days
1, 3 or 7, the mice were sacrificed, the tumors removed and the
paraffin-embedded tissue sections were stained with VEGF
antibody. Each dot represents the mean number (including the
standard error of the mean [SEM]) of the blood microvessels
calculatedfrom tumors resectedfrom three d ifferent mice
*P<0.05.
Sarcoma, angiogenesis, tumor necrosis factor, animal model 59protein in blood microvessel endothelial cells. At day
1 the increase in the mean staining level in TNF-a
compared to HBSS-injected mice was from 2.0 to
2.2 at day 1 (10% increase), from 1.9 to 2.6 (37%
increase) at day 3 and from 1.6 to 2.1 (31%) at day 7.
Discussion
Malignant soft tissue tumors, sarcomas, account for
less than 1% of all invasive neoplasms, but they often
exhibit highly malignant behavior and cause at least
20% of all deaths from malignant diseases.
21 Among
the different factors which modulate the growth of
tumors, the generation of new blood vessels in the
tumor, a process known as angiogenesis, plays a
pivotal role.
1,2 Thus, the ability to modulate this
process is enormously important.
In the present study, we tested the ability of
TNF-a to modulate the endothelial cells in the blood
microvessels of the MCA205 fibrosarcoma murine
tumor. Our results showed that an i.p. injection of
10mg TNF-a caused a substantial reduction in the
number of tumor blood microvessels compared to
the number of blood microvessels counted in the
tumor-bearing mice which received HBSS alone.
A maximal reduction of 46% was observed 3 days
post-TNF-a injection, as assessed by both VEGF
and Factor 8 antibodies. Furthermore, monitoring
tumor growth following TNF-a injection revealed a
substantial reduction in tumor growth rate, starting
19 days post-cytokine injection, compared to the
HBSS-treated control mice. Others have shown that
TNF may cause the necrosis of s.c. tumors within
hours following the injection of the cytokine.
14 Such
a rapid response may be the result of employing
higher concentrations of the cytokine or a different
route of injection, e.g., intravenously. It is also
possible that the effect of TNF in our study was due
to a delayed antitumor cell-mediated immune
response.
15 In order to further explore this possibi-
lity, experiments aimed at delineating the role of a
cell-mediated immune response in the described
experimental model are currently being conducted
on mice with an impaired immune system.
In contrast to our current findings, other investi-
gators have failed to demonstrate any effect of
TNF-a on tumor vascularization or to show an
increase in angiogenesis.
4,7–9 Such differences in
results could be explained by the dose, injection
regimen and route of administration of the cytokine,
all of which may affect the concentration of the
cytokine reaching the tumor site. It is also possible
that endothelial cells in various tumors may differ in
the expression of specific receptors for TNF-a,
16 a
feature which would affect their sensitivity to TNF-a
activity. Alternatively, since tumor-associated macro-
phages (TAM) were shown to modulate angiogenesis
via the secretion of IL-8, VEGF, GM-CSF, IL-1a
and TNF-a,
4,8,17 changes in the number of these
cells within various tumors or their activation levels
may modulate the effect of TNF-a on tumor angio-
genesis following its injection into tumor-bearing
mice.
The mechanisms involved in the herein described
effects of TNF-a on the endothelial cells in the blood
microvessels is not fully understood. One possible
mechanism is the destruction of endothelial cells
through apoptosis: this is supported by our findings
demonstrating that TNF-a increased the expression
of p53 in the endothelial cells in the blood micro-
vessels by up to 37% when compared to HBSS-
injected mice at 3 days post-injections. These
findings, however, do not exclude the possibility
that TNF-a exerts a cytotoxic signals via a different
mechanism, including the generation of free oxygen
radicals
18 which were shown to affect the endothelial
cells in the blood microvessels
19 by activation of the
nuclear factor-k B.
20
We demonstrated the effect of TNF-a on an
established murine fibrosarcoma line and contend
that this was probably through the modulation of the
growth of the endothelial cells in the blood micro-
vessels. Experiments to delineate the combined effect
of TNF-a with other modulators as well as the
mechanism by which this cytokine regulates blood
microvessels endothelial cells in murine sarcoma are
currently underway.
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